Disease flare after tyrosine kinase inhibitor (TKI) discontinuation in patients with EGFR-mutant lung cancer and acquired resistance

被引：0
|
作者：
Chaft, J. E. [1 ]
Oxnard, G. R. [1 ]
Miller, V. A. [1 ]
Kris, M. G. [1 ]
Sima, C. S. [1 ]
Riely, G. J. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18001
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Tepotinib with an EGFR-tyrosine kinase inhibitor (TKI) in patients with EGFR-mutant MET-amplified NSCLC: A case series
    Lam, Wei-Sen
    Le, Xiuning
    Eisert, Anna
    Himpe, Ulrike
    De Bondt, Charlotte
    Mazieres, Julien
    Petrini, Iacopo
    Tho, Lye Mun
    Ahmad, Azura
    Chik, Yin Kwan Jeannie
    Chung, Wai
    Lee, Kirsty
    Yang, Tsung-Ying
    Hsia, Te-Chun
    Joshi, Kirti
    Young, Louise
    Berghoff, Karin
    Vlassak, Soetkin
    Karachaliou, Niki
    van der Wekken, Anthonie
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 83 - 84
  • [22] Tepotinib with an EGFR-tyrosine kinase inhibitor (TKI) in patients with EGFR-mutant MET-amplified NSCLC: A case series
    Ahmad, A. R.
    Tho, L. M.
    Chik, Y. K. J.
    Lee, W. C. K.
    Yang, T-Y.
    Le, X.
    Eisert, A. K.
    Himpe, U.
    De Bondt, C.
    Mazieres, J.
    Petrini, I.
    Lam, W-S.
    Joshi, K.
    Berghoff, K.
    Vlassak, S.
    Karachaliou, N.
    Van der Wekken, A. J.
    Hsia, T-C.
    ANNALS OF ONCOLOGY, 2022, 33 : S1584 - S1584
  • [23] MET Status before Tyrosine Kinase Inhibitor (TKI)-Start Predicts Treatment Responses in EGFR-Mutant Lung Adenocarcinoma
    Meyer, A-S K.
    Marienfeld, R.
    Rudiger, S.
    Muller, P.
    Moller, P.
    Schumann, C.
    Lennerz, J. K.
    MODERN PATHOLOGY, 2014, 27 : 488A - 488A
  • [24] Tepotinib with an EGFR-Tyrosine Kinase Inhibitor (TKI) in Patients with EGFR-mutant MET-amplified NSCLC: A Case Series
    Le, X.
    Eisert, A.
    Himpe, U.
    De Bondt, C.
    Mazieres, J.
    Petrini, I.
    Tho, L. M.
    Ahmad, A.
    Lam, W. -S.
    Chik, Y. K. J.
    Lee, W. C. K.
    Yang, T. -Y.
    Joshi, K.
    Berghoff, K.
    Vlassak, S.
    Karachaliou, N.
    v. d. Wekken, A.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S483 - S484
  • [25] Mammalian SWI/SNF chromatin remodeling complexes promote tyrosine kinase inhibitor resistance in EGFR-mutant lung cancer
    de Miguel, Fernando J.
    Gentile, Claudia
    Feng, William W.
    Silva, Shannon J.
    Sankar, Akshay
    Exposito, Francisco
    Feng, Wesley L.
    Melnick, Mary Ann
    Robles-Oteiza, Camila
    Hinkley, Madeline M.
    Tsai, Jeanelle A.
    Hartley, Antja-Voy
    Wei, Jin
    Wurtz, Anna
    Li, Fangyong
    Toki, Maria I.
    Rimm, David L.
    Homer, Robert
    Wilen, Craig B.
    Xiao, Andrew Z.
    Qi, Jun
    Yan, Qin
    Nguyen, Don X.
    Janne, Pasi A.
    Kadoch, Cigall
    Politi, Katerina A.
    CANCER CELL, 2023, 41 (08) : 1516 - +
  • [26] Intrinsic Resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance
    Santoni-Rugiu, Eric
    Melchior, Linea C.
    Urbanska, Edyta M.
    Jakobsen, Jan N.
    de Stricker, Karin
    Grauslund, Morten
    Sorensen, Jens B.
    CANCERS, 2019, 11 (07)
  • [27] Targeting BRAF Activation as Acquired Resistance Mechanism to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small-Cell Lung Cancer
    Aboubakar Nana, Frank
    Ocak, Sebahat
    PHARMACEUTICS, 2021, 13 (09)
  • [28] TGFβ1/integrin β3 positive feedback loop contributes to acquired EGFR TKI resistance in EGFR-mutant lung cancer
    Wang, Tao
    Zhang, Yali
    Cheng, Hanyue
    Li, Ling
    Xu, Lu
    JOURNAL OF DRUG TARGETING, 2023, 31 (03) : 269 - 277
  • [29] Combined Therapy with Mutant-Selective EGFR Inhibitor and Met Kinase Inhibitor for Overcoming Erlotinib Resistance in EGFR-Mutant Lung Cancer
    Nakagawa, Takayuki
    Takeuchi, Shinji
    Yamada, Tadaaki
    Nanjo, Shigeki
    Ishikawa, Daisuke
    Sano, Takako
    Kita, Kenji
    Nakamura, Takahiro
    Matsumoto, Kunio
    Suda, Kenichi
    Mitsudomi, Tetsuya
    Sekido, Yoshitaka
    Uenaka, Toshimitsu
    Yano, Seiji
    MOLECULAR CANCER THERAPEUTICS, 2012, 11 (10) : 2149 - 2157
  • [30] Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
    Yu, Helena A.
    Arcila, Maria E.
    Rekhtman, Natasha
    Sima, Camelia S.
    Zakowski, Maureen F.
    Pao, William
    Kris, Mark G.
    Miller, Vincent A.
    Ladanyi, Marc
    Riely, Gregory J.
    CLINICAL CANCER RESEARCH, 2013, 19 (08) : 2240 - 2247
12345